Prognostic Value of Quantitative 18F-FDG PET/CT Parameters Measured in Primary Tumors and Suspicious Lymph Nodes in Patients With Esophageal Carcinoma

Francisco Tustumi (✉ franciscotustumi@gmail.com)  
Universidade de Sao Paulo  https://orcid.org/0000-0001-6695-0496

Flávio Roberto Takeda  
Universidade de Sao Paulo

Paulo Schiavom Duarte  
Universidade de Sao Paulo

David Gutiérrez Albenda  
Universidade de Sao Paulo

Rubens Antonio Aissar Sallum  
Universidade de Sao Paulo

Ulysses Ribeiro Junior  
Universidade de Sao Paulo

Carlos Alberto Buchpiguel  
Universidade de Sao Paulo

Ivan Cecconello  
Universidade de Sao Paulo

Research article

Keywords: Esophageal neoplasms, Neoadjuvant therapy, PositronEmission Tomography, Nuclear Medicine

DOI: https://doi.org/10.21203/rs.3.rs-32577/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective:

Quantitative $^{18}$F-FDG PET/CT parameters have been described as prognostic indicators in esophageal cancer. The objective of this study is to evaluate the prognostic value of the maximum standardized uptake value (SUVmax), metabolic tumor value (MTV) and total lesion glycolysis (TLG) measured in the primary tumor and suspicious lymph nodes.

Methods:

A cohort study was performed to assess the association of SUVmax, MTV and TLG measured prior to and post neoadjuvant therapy with overall survival (OS) of patients with esophageal cancer who received trimodal therapy. The quantitative techniques were applied in the primary tumor and suspicious lymph nodes. The OS rates were analyzed.

Results:

Before neoadjuvant therapy, 106 patients underwent PET/CT, and 39 patients underwent post-neoadjuvant therapy PET/CT exams. Before neoadjuvant therapy, PET/CT showed that all the variables of the evaluated lymph nodes were statistically significant in predicting OS. Postneoadjuvanttherapy, none of the PET/CT variables of lymph nodes were related to prognosis. On the other hand, all primary tumor volumetric variables were related to overall survival. The MTV (HR: 4.66; 95% CI: 1.54-14.08) and TLG (HR: 4.86; 95% CI: 1.66-14.26) of the primary tumor post neoadjuvanttherapy and the variations in MTV (HR: 2.95; 95% CI: 1.01-3.52) and TLG (HR: 3.49; 95% CI: 1.01-3.52) of the primary tumor pre-to-post-neoadjuvanttherapy were prognostic variables.

Conclusion:

In patients with esophageal cancer, the burden of disease in suspicious lymph nodes and the primary tumor prior to therapy and the residual burden of disease in the primary tumor post therapy assessed by PET/CT were associated with prognosis.

1. Introduction

Since the CROSS group $^1$ reported good results after neoadjuvant therapy based on carboplatin and paclitaxel, preoperative chemoradiotherapy has become the mainstay treatment among most patients with potentially curable esophageal cancer. $^{1, 2}$ On the other hand, patients with poor response to neoadjuvant therapy present poor long-term survival rates and might not be the best candidates for surgical resection. $^3$ To reach the correct treatment decisions and to reduce therapeutic toxicity, the selection of patients who have favorable prognoses plays an important role.
F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) provides the ability to functionally evaluate metabolic activity, thus improving patient selection for surgical treatment.

The pretreatment standardized uptake value (SUV) is the most widely used parameter in 18F-FDG PET/CT and is considered a prognostic factor for risk stratification; however, this parameter does not reflect the heterogeneity of the primary tumor or lymph nodes. Aggressive tumors grow rapidly and usually present intratumoral hypoxia and necrosis, which leads to heterogeneous FDG accumulation in the tumor. In this context, volume-based parameters such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) that reflect metabolic volume and activity in an entire mass, respectively, have been proposed as quantitative indexes of tumor metabolism. MTV is a volumetric measure of the tumor cells with high glycolytic activity, while TLG is defined as the product of the tumor volume by the average SUV inside this volume. These indexes are prognostic indicators for survival in several neoplasms, such as lung cancer, pleural mesothelioma, ovarian cancer, and head and neck cancer.

There have been a few studies on the prognostic value of MTV and TLG for esophageal cancer treated with trimodal therapy. Nonetheless, these studies included heterogeneous neoadjuvant therapy regimens and did not present separate analyses of primary tumors and lymph nodes.

Therefore, the aim of this study is to assess the value of the maximum SUV (SUVmax), MTV and TLG of the primary tumor and suspicious lymph nodes, as measured with 18F-FDG PET/CT prior to and post therapy, in predicting overall survival in a group of patients with esophageal cancer treated with neoadjuvant chemoradiotherapy using a platinum- and taxane-based regimen followed by curative intent esophagectomy.

2. Methods

A retrospective cohort study was performed in a group of patients with esophageal cancer, assessing the association of SUVmax and volumetric parameters (MTV and TLG) measured on 18F-FDG PET/CT studies performed prior and post neoadjuvant therapy, as well as the variations in these values pre-to-post neoadjuvant therapy, with overall survival (OS). The 18F-FDG PET/CT parameters of both the primary tumor and lymph nodes were estimated (see Fig. 1).

2.1 Patients

The patients originated from a single institute and completed neoadjuvant chemoradiotherapy using platinum- and taxane-based regimens, followed by curative intent esophagectomy. A transthoracic approach with two-field lymph node dissection was performed for tumors extending proximally to the tracheal bifurcation. For tumors involving the esophagogastric junction, a transhiatal resection was preferred. Gastric tube reconstruction with cervical anastomosis was the preferred technique.
The recruitment period ranged from 2009 to 2019. Patients were staged with endoscopy, CT, and PET and classified according to the 8th edition of the UICC staging system. The local ethics committee approved the study.

2.2 $^{18}$F-FDG PET/CT acquisition and imaging analyses

$^{18}$F-FDG PET/CT scans were acquired on a Discovery 690 with time-of-flight (General Electric, Waukesha, Wisconsin, USA). The patients were injected with $\sim 3.7$ MBq $^{18}$F-FDG per kg body weight. The patients were instructed to fast for at least 6 h and had a blood glucose level below 180 mg/dl before the radiopharmaceutical injection. Imaging was initiated 60 min after the injection, and the scans were acquired from the mid-skull to mid-thigh. The images were reconstructed with a standard iterative algorithm, and the burden of disease in the primary tumor and metastatic lymph nodes were evaluated using SUVmax, TLG and MTV. These variables were calculated by a nuclear medicine physician using AW VolumeShare 5® (General Electric, Waukesha, Wisconsin, USA). The SUV thresholds used to define the boundaries of the lesions were established by visual analysis, and the total volumes of interest that circumscribed the primary tumor and metastases were calculated automatically by the software.

The burden of the disease was measured on $^{18}$F-FDG PET/CT scans acquired prior to and post neoadjuvant therapy.

2.3 Statistical analyses

Survival analysis was performed with Kaplan-Meier and log-rank tests. For long-term survival analysis, all patients who died within 30 days postoperatively were excluded from the analysis, and the cutoff was defined as the threshold value of the continuous covariate determined by Lausen. A significance level of 0.05 was adopted. Cox proportional hazard analysis was performed. In the multivariate analysis, the $^{18}$F-FDG PET/CT parameters, age, sex, clinical stage, and grade of cellular differentiation were assessed.

3. Results

3.1 Patients’ baseline characteristics

One hundred seventeen patients underwent neoadjuvant chemoradiotherapy using platinum- and taxane-based regimens followed by curative intent esophagectomy and were included. Of these patients, 8 patients who died within 30 days postoperatively were excluded. One hundred and six patients underwent PET/CT before neoadjuvant therapy, and 39 of these patients also had post-neoadjuvant therapy PET/CT exams. Squamous cell carcinoma (SCC) comprised 70% of the cases, and adenocarcinoma comprised the remaining cases. The mean follow-up was 36.8 months (SD $\pm$ 24.9), with a mean age of 60.9 years (SD $\pm$ 8.2), and there was a male predominance (78.9%). There were 87 transthoracic (video-assisted thoracoscopic) procedures and 22 transhiatal procedures, all of which involved cervical anastomosis. The median time from the completion of neoadjuvant chemoradiotherapy to surgery was 13.4 ($\pm$ 6) weeks. The two chemotherapy regimens adopted were carboplatin and paclitaxel (78%) and cisplatin and
paclitaxel (22%). The radiation therapy dosages were 41.4 cGy (75.3%), 45 cGy (12.8%), and 50.4 cGy (11.9%). See Table 1.

| N | Pre neoadjuvant therapy PET | 106 |
|---|-----------------------------|-----|
|   | Post neoadjuvant therapy PET | 39  |

Table 1
Patients’ baseline characteristics. CRT: Chemoradiotherapy.

|   | Pre neoadjuvant therapy PET | 106 |
|---|-----------------------------|-----|
|   | Post neoadjuvant therapy PET | 39  |
| **Age (years; mean ± SD)** | 60.9 | 8.2 |
| **Sex (n, %)** | Male | 86 | 78.9 |
| | Female | 23 | 21.1 |
| **Histology (n, %)** | Adenocarcinoma | 32 | 29.4 |
| | SCC | 77 | 70.6 |
| **Clinical stage (n, %)** | I/II | 33 | 30.3 |
| | III/IV | 76 | 69.7 |
| **Grade of cellular differentiation (n, %)** | I | 8 | 7.3 |
| | II | 75 | 68.9 |
| | III | 26 | 23.8 |
| **Radiation therapy (n, %)** | 41.4 | 82 | 75.3 |
| | 45 | 14 | 12.8 |
| | 50.4 | 13 | 11.9 |
| **Chemotherapy regimen (n, %)** | Cisplatin/paclitaxel | 24 | 22 |
| | Carboplatin/paclitaxel | 85 | 78 |
| **Time interval between CRT and surgery (weeks; median ± IQR)** | 13.4 | 6 |
| **Surgical access (n, %)** | Transhiatal | 22 | 20.2 |
| | Thoracoscopic | 87 | 78.8 |
| **Lymph nodes dissected (mean ± SD)** | 21.4 | 12.7 |
| **Cervical leakage (n, %)** | 28 | 25.7 |

3.2 Overall survival
Prior to neoadjuvant therapy, $^{18}$F-FDG PET/CT showed that all the variables of the evaluated lymph nodes were statistically significant in predicting long-term survival (See Fig. 2). The MTV of the primary tumor (HR: 1.89; 95% CI: 1.01–3.52; $p = 0.04$) was also able to predict overall survival. See Table 2.
Table 2
The relationship between the $^{18}$F-FDG PET/CT variables and overall survival.

| Variable                  | All cases | Adenocarcinoma | Squamous cell carcinoma |
|---------------------------|-----------|-----------------|-------------------------|
|                           | Cut-off point | HR | 95% CI | p-value | Cut-off point | HR | 95% CI | p-value | Cut-off point | HR | 95% CI | p-value |
| Patient stage             | S    | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 |
|                           | M    | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 |
|                           | T    | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 |
|                           | L    | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 |
|                           | C    | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 |
|                           | V    | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 |
|                           | P    | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 | 2.0 | 4.0 | 0.6 | 0.9 |

Note: The table continues with additional rows and columns providing further data for each variable.
| Antimetabolites | 2 | 3 | 2 | 3 |
|-----------------|---|---|---|---|
| T               | ≥ 4.1.0.0 | ≥ N NN | ≥ 1.0.7.0.9 |
| L              | 5.8.6.4.0 | E E E E | 5.5.33.67.56 |
| G              | 9.6.6.2.0 | 5.9 | 9.5 |

| Lymph nodes | 2 | 3 | 2 | 3 |
|-------------|---|---|---|---|
| S U V m ax | ≥ 1.0.4.0 | ≥ N NN | ≥ 1.0.5.0.94 |
|             | 2.2.3.5.7 | 0 E E E E | 2.0.22.14.94 |
|             | 9.6.5.3.4 | 7 6 | 7 6 |

| T L G         | 1.4.3.6.6 | 0 E E E E | 1.5.9.8.02 |
|---------------|-----------|-----------|------------|
| Primo tumor   | 2 | 3 | 2 | 3 |
| S U V m ax   | ≥ 2.0.8.0 | ≥ N NN | ≥ 2.0.18.0.07 |
|              | 1.8.9.0.0 | 0 0 (-) 0 | 1.8.06.52 |
|              | 9.1.8.7.5 | 6 5 | 9 6 |

| T L G         | 3.2.4.0.2 | 0 E E E E | 3.8.79.60.07 |
|---------------|-----------|-----------|------------|
| Variation pre- | 2 | 3 | 2 | 3 |
| post neo adjuvant therapy | | | | |
| S U V m ax   | ≥ 2.0.1.0 | ≥ N NN | ≥ 2.0.18.0.07 |
|              | 1.9.0.5.0 | 0 0 (-) 0 | 1.8.06.52 |
|              | 9.5.1.9.4 | 4 3 | 9 4 |

| T L G         | 3.4.9.2.0 | 0 E E E E | 3.8.79.60.07 |
|---------------|-----------|-----------|------------|
| Antimetabolites | 2 | 3 | 2 | 3 |
| T               | ≥ 3.0.1.0 | ≥ N NN | ≥ 2.0.18.0.07 |
| L              | 6.4.9.2.0 | 0 0 (-) 0 | 1.8.06.52 |
| G              | 2.9.6.7.4 | 6 4 | 6 4 |

| T L G         | ≥ 0.0.5.0 | ≥ N NN | ≥ 2.0.18.0.07 |
|---------------|-----------|-----------|------------|
| Primo tumor   | 2 | 3 | 2 | 3 |
| S U V m ax   | ≥ 0.0.5.0 | ≥ N NN | ≥ 2.0.18.0.07 |
|              | 4.7.0.4.1 | 0 0 (-) 0 | 1.8.06.52 |
|              | 5.1.9.8.4 | 5 4 | 5 4 |

| T L G         | 2.3.4.0.2 | 0 E E E E | 2.0.12.0.17 |
|---------------|-----------|-----------|------------|
| Variation pre- | 2 | 3 | 2 | 3 |
| post neo adjuvant therapy | | | | |
| S U V m ax   | ≥ 2.0.1.0 | ≥ N NN | ≥ 2.0.18.0.07 |
|              | 1.7.0.4.1 | 0 0 (-) 0 | 1.8.06.52 |
|              | 8.5.1.9.4 | 4 3 | 4 3 |

| T L G         | ≥ 0.0.5.0 | ≥ N NN | ≥ 2.0.18.0.07 |
|---------------|-----------|-----------|------------|
| Antimetabolites | 2 | 3 | 2 | 3 |
| T               | ≥ 0.0.5.0 | ≥ N NN | ≥ 2.0.18.0.07 |
| L              | -2.3.4.0.2 | 0 E E E E | 4.7.93.80.04 |
| G              | 9.6.5.3.4 | 5 9 | 5 9 |
For lymph nodes, none of the post neoadjuvant therapy $^{18}$F-FDG PET/CT variables or the variations pre-to-post neoadjuvant therapy were related to prognosis. On the other hand, all volumetric variables of the primary tumor were related to overall survival (See Fig. 3). The MTV (HR: 4.66; 95% CI: 1.54–14.08; $p$ = 0.00) and TLG (HR: 4.86; 95% CI: 1.66–14.26; $p$ = 0.00) of the primary tumor post neoadjuvant therapy and the variations in the MTV (HR: 2.95; 95% CI: 1.01–3.52; $p$ = 0.04) and TLG (HR: 3.49; 95% CI: 1.01–3.52; $p$ = 0.04) of the primary tumor pre-to-post-neoadjuvant therapy were prognostic variables. See Table 2.

In the subgroup analysis, none of the variables related to adenocarcinoma were statistically significant. On the other hand, for squamous cell carcinoma (SCC), the SUVmax and TLG of lymph nodes prior to neoadjuvant therapy; MTV of lymph nodes after neoadjuvant therapy; and the variations in the SUVmax of the primary tumor and TLG of lymph nodes were related to survival. See Table 2.

In the logistic regression, only age and the change in MTV value after neoadjuvant therapy were considered independent variables related to OS. See Table 3.

### Table 3
Multivariate analysis.

| Variable | Group | HR  | 95% CI  | $P$-value |
|----------|-------|-----|---------|-----------|
|          |       |     | Lower   | Upper     |
| Age      |       | 1.11| 1.03    | 1.20      | **0.01**  |
| Variation pre-to-post neoadjuvant therapy | Primary tumor | $\geq$ 12.93 | 3.13 | 1.07 | 9.18 | **0.04** |

### 4. Discussion

The results of this cohort of esophageal cancer patients who underwent neoadjuvant chemoradiotherapy using a platinum- and taxane-based regimen followed by curative intent esophagectomy suggest that the absolute values of and changes in some of the quantitative $^{18}$F-FDG PET/CT variables predict survival. The lymph node parameters pre neoadjuvant therapy and the primary tumor parameters post neoadjuvant therapy are prognostic factors, mainly for SCC.

MTV and TLG are parameters that reflect both tumor volume and metabolic activity. These parameters provide complementary information about disease burden. In this study, the change in metabolic volume after neoadjuvant therapy and age were unique independent variables related to survival. Although the SUV parameters were related to OS in the univariate analysis, they were not considered independent
variables in the final model. SUVmax and SUVmean are semiquantitative indexes that might fail to reflect the spatial distribution of lesions and could vary with different PET scanners, fasting duration, level of plasma glucose and region of interest (ROI). TLG, which is dependent on SUVmean, may also be influenced.

A few studies have assessed SUVmax as a prognostic factor for survival. In addition, several recent studies revealed that the pretreatment MTV and TLG have prognostic value in the prediction of survival in surgically resected or inoperable esophageal cancer. However, these studies used heterogeneous neoadjuvant regimens or surgical approaches, and none of them evaluated metabolic volumetric changes in the lymph nodes. Additionally, these studies used different cut-off points for the logistic regression for survival analysis. The present study used the Lausen cut-off point, which is more suitable for survival analysis when patients are followed for different intervals.

The results of this study should be interpreted in the context of certain inherent limitations. This is a single-center retrospective study with a relatively small sample size and is mainly focused the period after neoadjuvant therapy. Larger and controlled prospective studies are warranted to clarify the predictive value of these PET/CT variables on prognosis.

Despite these limitations, this is the first study to assess the relationship between changes in PET/CT variables and survival during neoadjuvant chemoradiotherapy with a platinum- and taxane-based regimen followed by curative intent esophagectomy to treat cancer.

5. Conclusion

PET/CT is a noninvasive imaging method that functionally evaluates metabolic activity, and the absolute values of and changes in SUVmax and volumetric variables provide important information on patient prognosis and may improve patient selection for surgical treatment. Measuring metabolic parameters offers an easy approach towards determining patient prognosis, as the majority of patients receive PET/CT during staging. Clinicians can predict which patients will respond favorably to neoadjuvant therapy and esophagectomy and customize the follow-up of each patient. Personalized medicine is a goal of modern cancer therapy and aims for individually optimized treatments that are dependent on the tumor characteristics of each individual patient.

Declarations

Ethics approval and consent to participate

Local Ethics committee (CCEP) approved this study.

Consent for publication

Not applicable
Availability of data and material

The data that support the findings of this study are available from the corresponding author but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the corresponding author.

Competing interests

The authors declare that they have no competing interests.

Funding

The authors received no specific funding for this work.

Authors’ contributions

- FT: Acquisition of the data.
- FRT: Acquisition, analysis and interpretation of the data.
- PD: Acquisition of the data.
- DA: Revising critically the work.
- CB: Revising critically the work.
- URJ: Statistical analysis and interpretation of the data
- RAAS: Drafting of the study.
- IC: Drafting and supervision of the study.

Acknowledgements

Not applicable.

References

1. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May;31(22):2074–84. 366(.
2. Mota FC, Cecconello I, Takeda FR, Tustumi F, Sallum RAA, Bernardo WM. Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options. Int J Surg. 2018 Jun;54(Pt A):176–81.
3. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec;31(27):1979–84. 339(.
4. Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohe H, Yamakado K. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0. Eur J Radiol. 2018 Apr;101:65–71.

5. Meyers BF, Downey RJ, Decker PA, Keenan RJ, Siegel BA, Cerfolio RJ, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007 Mar;133(3):738–45.

6. Mac Manus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1298–306.

7. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013 Sep 19;501(7467):328–37.

8. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med. 1995 Oct;36(10):1854–61.

9. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A. 2011 Sep;20(38):16062–7. 108(.

10. Chang S, Kim SJ. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters. Cancer Biother Radiopharm. 2016 Feb;31(1):1–6.

11. Cacicedo J, Navarro A, Del Hoyo O, Gomez-Iturriaga A, Alongi F, Medina JA, et al. Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. Br J Radiol. 2016 Nov;89(1067):20160217.

12. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012 Jun;19(6):1966–72.

13. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012 May;53(5):709–15.

14. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of 18) F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010 Oct;17(10):2787–94.

15. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27–38.

16. Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012 Oct;53(10):1506–13.
17. Moon SH, Choi JY, Lee HJ, Son Yi, Baek CH, Ahn YC, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck. 2013 Jan;35(1):15–22.

18. Schwartz DL, Harris J, Yao M, Rosenthal DI, Opanowski A, Levering A, et al. Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. Int J Radiat Oncol Biol Phys. 2015 Mar;15(4):721–9. 91(.

19. Bütof R, Hofheinz F, Zöphel K, Stadelmann T, Schmollack J, Jentsch C, et al. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. J Nucl Med. 2015 Aug;56(8):1150–6.

20. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, et al. 18-fluorodeoxyglucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov;51(17):2545–52.

21. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1191–202.

22. Hofheinz F, Li Y, Steffen IG, Lin Q, Lili C, Hua W, et al. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2019 Apr 4.

23. Hong JH, Kim HH, Han EJ, Byun JH, Jang HS, et al. Total Lesion Glycolysis Using ¹³¹I-F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer. J Korean Med Sci. 2016 Jan;31(1):39–46.

24. Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):471-7.

25. Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Gouel P, et al. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2008–16.

26. Li Y, Lin Q, Luo Z, Zhao L, Zhu L, Sun L, et al. Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy. Int J Clin Exp Med. 2015 Jul;15(7):10947–55. 8(.

27. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017 Mar;6(2):119–30.

28. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48(1):73–85.

29. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010 Jan;17(1):115–22.
Figures

Figure 1
18F-FDG PET/CT. The parameters of both the primary tumor and lymph nodes were estimated.

Figure 2
Overall survival according to the 18F-FDG PET/CT parameters of lymph nodes prior to neoadjuvant therapy. Cut-off points were determined by Lausen.
Figure 3

Overall survival according to the 18F-FDG PET/CT parameters of the primary tumor post neoadjuvant therapy. Cut-off points were determined by Lausen.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Certificate.pdf